Analysts' Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA)
Confident Investing Starts Here:
Quince Therapeutics (QNCX)
In a report issued on June 4, Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics, with a price target of $6.00. The company's shares closed last Friday at $1.17.
According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.2% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quince Therapeutics with a $6.67 average price target.
Moderna (MRNA)
In a report released today, Matt Phipps from William Blair reiterated a Hold rating on Moderna. The company's shares closed last Friday at $27.46.
According to TipRanks.com, Phipps is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.1% and a 41.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Janux Therapeutics Inc.
Currently, the analyst consensus on Moderna is a Hold with an average price target of $49.29, an 88.1% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
19 hours ago
- Business Insider
Mixed options sentiment in Moderna with shares up 0.58%
Mixed options sentiment in Moderna (MRNA), with shares up 18c, or 0.58%, near $30.45. Options volume relatively light with 33k contracts traded and calls leading puts for a put/call ratio of 0.35, compared to a typical level near 0.56. Implied volatility (IV30) dropped 4.95 near 66.99,and below the 52wk median, suggesting an expected daily move of $1.29. Put-call skew steepened, indicating increased demand for downside protection. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
a day ago
- Yahoo
Moderna (NasdaqGS:MRNA) Joins Russell Midcap Indices In Late June 2025
In late June 2025, Moderna underwent significant index changes, adding to the Russell Midcap indices while exiting the Russell Top 200 indices. This reclassification might have signaled a shift in investor perception, aligning with the company's 18% share price increase over the last quarter. Despite the broader market experiencing a rally with indexes like the S&P 500 and Nasdaq reaching record highs, Moderna's earnings report, strategic alliances, and product-related updates added weight to its price movement. These developments occurred against a backdrop of economic optimism, with strong job growth boosting market sentiment. Buy, Hold or Sell Moderna? View our complete analysis and fair value estimate and you decide. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent index reclassification of Moderna into the Russell Midcap indices and removal from the Russell Top 200 indicates a shift in investor perception, possibly affecting long-term investor strategies. Despite a recent 18% share price increase over the past quarter coinciding with broader market highs, Moderna's five-year total return was a 50.83% decline. This underperformance relative to industry peers indicates the challenges Moderna faces, including decreased revenues and high costs impacting profitability. The news and developments around Moderna's strategic alliances and product updates could potentially bolster future revenue through international market expansion and oncology advancements. Analysts expect revenue growth driven by new product approvals, yet the company's earnings are still forecast to remain negative in the near term. Current share price movements reflect some investor optimism, trading below the consensus price target of US$47.59, suggesting room for growth, provided the company meets these expectations. Unlock comprehensive insights into our analysis of Moderna stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:MRNA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
Boston Globe
4 days ago
- Boston Globe
Moderna's flu vaccine hits goal, paving way for combo shot
Shares rose as much as 5.8 percent at the start of normal trading on Monday in New York. Advertisement Moderna believes packaging the two immunizations together will lead to higher uptake of COVID vaccines. Nearly half of American adults get an annual flu shot, while only about 23 percent got the latest COVID vaccine. Moderna's flu shot, which uses mRNA technology, also could contribute to a longtime public health goal: a better standalone flu shot. That mission has only become more urgent after the US just experienced by some measures its worst flu season in 15 years. This year's flu vaccines were 56 percent effective. The company will seek approval for both its standalone flu shot and its COVID-flu combination vaccine, said Jacqueline Miller, Moderna's chief medical officer. The flu vaccine 'is such a central component of our strategy,' Miller said in an interview, adding that a combination COVID-flu shot could entice someone who 'is put off by getting two injections at once.' Advertisement Moderna's technology can make vaccines faster than the standard method, which requires growing the live virus in chicken eggs then inactivating it. That could make it easier to match the vaccine to the dominant strains that are circulating each season. The results are a rare bright spot for a company that has struggled with the decline of its COVID business and more recently, the new leadership of Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. Under Kennedy, US health officials have rolled back long-standing recommendations around COVID shots for children and pregnant women, approved Moderna's updated COVID shot for a narrower group of people and terminated the company's contract to develop bird flu vaccines. After the bird flu vaccine contract cancellation, the company has been 'actively seeking other funding sources' and is considering advancing the vaccine on its own, Miller said. Moderna's flu program has been on a tumultuous path. Over two years ago, the company's standalone flu vaccine yielded mixed results. Several months later, the company reported that a reformulated version produced a stronger immune response. Last year, the company said it would focus its resources on seeking approval for a flu and COVID combination vaccine because it said it would have a bigger impact.
